1. ALLA AKTIER
  2. NYHETER
  3. EXPRES2ION BIOTECH

ExpreS2ion Biotech

Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.
Datum Rubrik Källa
2026-02-23 14:00 ExpreS2ion Provides Update on Investor Engagement Following Q4 and Full-Year 2025 Results MFN
2026-02-19 08:30 ExpreS2ion Announces Financial Results for the Full-Year and Fourth Quarter of 2025 MAR MFN
2026-02-03 14:47 ExpreS2ion Biotech announces Redeye initiation of coverage with base case valuation of SEK 28 per share MFN
2026-02-03 10:54 ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial of ES2B-C001 MAR MFN
2026-01-28 13:45 As Nipah Virus Outbreaks in India Re-emerge, ExpreS2ion Selects Northway Biotech as Manufacturing Partner for Vaccine Program MARKN. MFN
2026-01-20 14:00 Subscriber Action Required: ExpreS2ion Press Release Distribution Moves to MFN Cision
2026-01-19 10:26 ExpreS2ion to Participate in Key Investor Event in January 2026 Cision
2025-12-19 11:45 ExpreS2ion Reports Updated Immunogenicity Data from First Three Patients and DSMB Recommendation to Progress ES2B-C001 Phase I Trial to Next Dose Cohort REG Cision
2025-11-13 08:30 ExpreS2ion Announces Financial Results for the First Nine Months and Third Quarter of 2025 REG Cision
2025-11-12 14:20 Correction: ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines REG Cision
2025-11-12 12:29 ExpreS2ion and Serum Institute of India Enter Definitive Licensing Agreement for Malaria Vaccines REG Cision
2025-11-10 10:00 Oxford-Led Malaria Vaccine Trials Using ExpreS2ion Platform Advance Through Clinical Phases REG Cision
2025-11-07 14:00 ExpreS2ion Hereby Changes Certified Advisor to Redeye REG Cision
2025-11-03 14:00 ExpreS2ion to Participate in Key Investor and Industry Events in November 2025 Cision
2025-10-08 14:00 VICI-Disease Consortium Finalizes Nipah Vaccine Antigen, Initiates Production Phase Cision
2025-10-06 16:12 ExpreS2ion Biotechnologies: Warrants of Series TO 11 Were Exercised to Approximately 88.5 Percent, ExpreS2ion Receives Approximately SEK 10.4 Million and Resolves on Directed Issues to Guarantors REG Cision
2025-09-15 08:16 ExpreS2ion Obtains Top Guarantee Commitments and Subscription Commitments for Warrant Program TO 11, Reflecting Continued Support and Reinforcing Funding REG Cision
2025-09-12 21:02 ExpreS2ion Announces TO 11 Warrant Exercise Price and Start of Exercise Period REG Cision
2025-09-12 10:00 ExpreS2ion to Present in Upcoming Investor Events Cision
2025-09-04 08:45 ExpreS2ion Reports First Immunogenicity Data from HER2 Breast Cancer Vaccine ES2B-C001 Phase I Trial REG Cision
2025-09-02 11:00 ExpreS2ion Biotech Highlights CEO Presentations at Økonomisk Ugebrev and ProHearings Investor Events Cision
2025-08-27 15:15 ExpreS2ion Biotech Announces Analysguiden Publishes Updated Equity Research Report; Price Target Maintained at SEK 75 Cision
2025-08-21 14:00 ExpreS2ion Biotech Announces Pareto Securities Analyst Note on Q2 2025 Results; Buy Rating Maintained with Price Target at SEK 303 Cision
2025-08-21 08:30 ExpreS2ion Announces Financial Results for the First Half and Second Quarter of 2025 REG Cision
2025-08-15 11:00 ExpreS2ion to Present in Upcoming Investor Events Cision
2025-07-18 11:50 ExpreS2ion Highlights Strategic Relevance of GHIT-Funded Malaria Vaccine Development Through Ownership in AdaptVac REG Cision
2025-07-07 10:10 ExpreS2ion enters strategic agreement with DTU for access to the Computerome supercomputer REG Cision
2025-06-30 14:57 Austrian Regulatory Green Light Enables ADC Combination Testing and Phase I Site Expansion for ES2B-C001, a First-in-Class Breast Cancer Immunotherapy REG Cision
2025-06-24 16:15 ExpreS2ion Biotech Announces Pareto Securities Analyst Note on First Patient Dosed in Phase I Trial Cision
2025-06-23 14:03 ExpreS2ion announces dosing of first patient in Phase I clinical trial of ES2B-C001, its novel therapeutic breast cancer immunotherapy REG Cision
2025-06-19 09:39 ExpreS2ion's associated company AdaptVac to lead CEPI and EU funded USD 12.4 million consortium to develop novel filovirus vaccine REG Cision
2025-05-28 11:30 Bulletin from the Annual General Meeting of Expres2ion Biotech Holding AB held on 28 May 2025 REG Cision
2025-05-23 13:29 ExpreS2ion Biotech Announces Analysguiden Publishes Equity Research Report Cision
2025-05-21 11:13 ExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress Cision
2025-05-15 08:30 ExpreS2ion announces financial results for the first quarter of 2025 REG Cision
2025-05-13 12:15 ExpreS2ion files clinical trial amendment to enable combination testing of ES2B-C001 with antibody-drug conjugates and to expand the number of study sites REG Cision
2025-05-09 13:00 ExpreS2ion to Present in Upcoming Investor Events Cision
2025-05-01 12:40 ExpreS2ion annual report for 2024 published REG Cision
2025-04-24 15:40 Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ) REG Cision
2025-04-24 15:39 Kallelse till årsstämma i ExpreS2ion Biotech Holding AB (publ) REG Cision
2025-04-15 08:45 ExpreS2ion signs Letter of Intent with WuXi Vaccines to initiate technology evaluation of ExpreS2ion's proprietary production platform ExpreS2™ REG Cision
2025-04-01 13:32 ExpreS2ion Provides Pipeline Update REG Cision
2025-03-31 17:40 ExpreS2ion Announces Leadership Transition in R&D REG Cision
2025-02-06 08:30 ExpreS2ion announces financial results for the fourth quarter of 2024 REG Cision
2025-01-09 11:00 ExpreS2ion to Present in Upcoming Investor and Scientific Events Cision
2024-12-11 12:10 Publication of clinical Phase IIb trial data for the adjuvanted RH5.1 blood-stage malaria vaccine Cision
2024-12-11 10:00 Analysguiden Publishes Research Report on ExpreS2ion Biotech with Price Target of SEK 91 Cision
2024-12-06 15:00 Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million REG Cision
2024-12-02 16:12 ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer REG Cision
2024-12-02 12:45 ExpreS2ion publishes video presentations from Biostock Life Science Summit and Analysguiden Stora Aktiedagarna Cision
Visa äldre nyheter